Dr. Jaffer Ajani on HLX22: A Potential New Approach for #her2positive #gastriccancer

What could the next generation of HER2-targeted therapy look like in gastric cancer?

In this interview, Dr. Jaffer Ajani — Global Principal Investigator of the HLX22-GC-301 trial and Chair of the NCCN Gastric and Esophageal Cancers Panel — discusses the differentiated mechanism of HLX22, ongoing unmet needs in #her2positive #gastriccancer , and why investigators are encouraged by the emerging clinical data.

The HLX22-GC-301 study is an ongoing international multicenter phase 3 trial in HER2-positive gastric cancer.

#Oncology #ClinicalTrials #CancerResearch

Видео Dr. Jaffer Ajani on HLX22: A Potential New Approach for #her2positive #gastriccancer канала Henlius